within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H03B_AntithyroidPreparations.H03BA03_Benzylthiouracil;

model Benzylthiouracil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 6.666666666666666e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0004,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Benzylthiouracil</td></tr><tr><td>ATC code:</td><td>H03BA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>40</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Benzylthiouracil is an antithyroid drug of the thiouracil class, historically used to manage hyperthyroidism by inhibiting thyroid hormone synthesis. Due to the risk of agranulocytosis and other adverse effects, it has been withdrawn from the market in many countries and is not commonly used today. It is not approved in the US or EU.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans after oral administration, as direct PK data is not available in referenced literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H03BA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Benzylthiouracil;
